"Men"

The development of an effective anti-aging drug and functional food to slow down ASCs' aging is crucial

H-Drugs in the leading international journal again!

According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!

Recently, the European Commission has approved cemiplimab-rwlc (Libtayo), manufactured by US-based Regeneron, as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-containing chemotherapy. The results of the trial showed that this therapy significantly improved patient survival and had a good safety profile.

Anemia is a very common problem among women. Anemia makes people less resistant and depressed, and serious anemia can also endanger the health of the body, so when the situation of anemia occurs, it should be promptly adjusted. The actual fact is that you will be able to get a lot more than just a few of the most popular and popular items.

Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.

New research by japanese scientists has found that

Results from a pivotal phase 3 trial show that the PD-1 therapy Keytruda, in combination with chemotherapy, significantly improves survival in patients with advanced gastric cancer and has a favorable safety profile. Patients benefited regardless of their PD-L1 expression.

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

Cervical cancer is one of the most common gynecological malignancies. Its incidence rate is second only to endometrial cancer worldwide, and it ranks first in developing countries and regions. According to statistics, there are 450000 new cases of cervical cancer worldwide every year. The occurrence and development of cervical cancer usually go through a relatively long process, so it is possible to prevent this disease.